Merck Serono SA

Merck Serono SA is a biopharmaceutical company that operates as a brand and division of Merck KGaA, a German science and technology company. While its former headquarters were in Geneva, Switzerland, Merck Serono moved its headquarters to Darmstadt, Germany, in 2012. Merck KGaA, founded in 1668, acquired Serono SA in 2006, leading to the formation of Merck Serono International SA in 2007. In the United States and Canada, the company operates as EMD Serono due to trademark considerations with Merck & Co. Inc. Merck KGaA, the parent company, employs almost 53,000 people globally.

Merck Serono focuses on the discovery, development, manufacturing, and marketing of innovative small molecules and biopharmaceuticals. Their product portfolio includes leading brands for various therapeutic areas, such as oncology (Erbitux), multiple sclerosis (Rebif, Mavenclad), infertility (Gonal-f, Ovidrel/Ovitrelle), endocrine and metabolic disorders (Saizen, Serostim, Glucophage, Euthyrox), and cardiovascular diseases (Concor). The company maintains a significant research and development expenditure, exceeding €1 billion annually.

Regarding patent litigation, Merck Serono SA appears as a plaintiff in the single tracked case in our database and has no defendant cases. This indicates an operating company that actively defends or asserts its intellectual property rights. The solitary tracked case, Merck Serono SA v. TWI Pharmaceuticals Inc., is being litigated at the United States Court of Appeals for the Federal Circuit (CAFC).